Phillip Frost News
-
Teva Pharmaceutical Industries Ltd., which just two years ago was analysts’ highest-rated stock among the world’s 20 biggest drugmakers, is struggling to convince investors that a key part of its strategy will revive growth.
-
Phillip Frost is among the top insider buyers in the U.S. as the pharmaceutical billionaire props up the shares of two of his companies following an acquisition agreement that has been contested by some investors.
-
Opko Health Inc. agreed to buy Israeli drugmaker Prolor Biotech Inc. for about $480 million to combine two companies that count U.S. pharmaceutical billionaire Phillip Frost as their largest shareholder.
-
ClickSoftware Technologies Ltd., the Israeli maker of workplace software, is rebounding from a five-month low after reiterating sales will rise as much as 25 percent as businesses boost spending on phone applications.
-
Teva Pharmaceutical Industries Ltd. is shifting away from the multi billion-dollar acquisitions that have defined its growth for the past decade, Chairman Phillip Frost said.
-
As American billionaire Phillip Frost prepared to take over as chairman of Teva Pharmaceutical Industries Ltd. in March 2010, some investors fretted about what would become of Israel’s crown jewel.
-
Phillip Frost, Miami-based chairman of Israel’s corporate crown jewel, says the drugmaker needs partnerships and small acquisitions to cure rising competition and falling shares.
-
Prolor Biotech Inc., an Israeli company developing improved versions of existing medicines, hired Jefferies Group Inc. to study strategic alternatives, according to a person with knowledge of the decision.
-
Barack Obama and Mitt Romney are on track to raise more than $1.5 billion to finance their presidential campaigns, and only an elite segment of the electorate will see them do it: their own donors.
-
After helping Bristol-Myers Squibb Co. find new drugs to help offset the expected loss of revenue from its top-selling blood thinner Plavix, Teva Pharmaceutical Industries Ltd.’s chief executive officer-designate Jeremy Levin faces the same task at the Israeli drugmaker.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page